Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986012 |
Synonyms | |
Therapy Description |
BMS-986012 is a monoclonal antibody that binds to the ganglioside fucosyl-GM1, which may lead to anti-tumor immune response (PMID: 30021910). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986012 | BMS 986012|BMS986012 | BMS-986012 is a monoclonal antibody that binds to the ganglioside fucosyl-GM1, which may lead to anti-tumor immune response (PMID: 30021910). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02247349 | Phase Ib/II | BMS-986012 BMS-986012 + Nivolumab | BMS-986012 in Relapsed/Refractory SCLC | Completed | USA | NLD | CAN | BEL | AUS | 2 |